Navigation Links
XDR-TB: Deadlier and more mysterious than ever

New research has found that XDR-TB is increasingly common and more deadly than previously known. Extensively drug-resistant tuberculosis (XDR-TB) is a growing public health threat that is only just beginning to be understood by medical and public health officials.

Patients with XDR-TB are four times as likely to fail treatment and three times more likely to die than patients with other forms of multi-drug-resistant TB (MDR-TB), according to a recent study that directly compared patients with XDR-TB to individuals with other types of MDR-TB to determine the differences in treatment outcomes and long-term survival rates. Researchers also found that MDR-TB was "a major threat to public health," representing 2.7 percent of new TB cases in South Korea in 2004, up from 1.6 percent in 1994.

The results were published in the second issue for November of the American Journal of Respiratory and Critical Care Medicine, a journal of the American Thoracic Society.

Since it appeared on the public health radar in 2006, XDR-TB rekindled an urgent interest in preventing, fighting and containing TB. But at the same time, little was known about how XDR-TB changed the face of combating TB on all fronts, from the perspective of the patient, the clinician and the public health official.

"Treatment outcomes [of XDR-TB] have varied among studies, and data on long-term survival are still scarce," wrote Tae Sun Shim, M.D., an associate professor at Asan Medical Center in Seoul, South Korea, and a principal investigator of the study. "[This] is the largest report that we know of that compares patients with XDR-TB with other patients with MDR-TB to determine the impact of XDR-TB on treatment outcomes and long-term survival in mostly HIV-negative patients with MDR-TB."

The study reviewed the medical records of more than 1,400 patients in South Korea with MDR-TB (which includes XDR-TB) from all national hospitals, Korean National TB Association chest clinics and select university hospitals. In addition to the patients' demographic information, their history of TB and previous treatments were noted with regard to outcome. In this study, XDR-TB was defined as MDR-TB resistant to both ofloxacin and at least one second-line injectable drug.

The researchers found that patients with XDR-TB were significantly older than MDR-TB patients, were more likely to have a history of treatment with second-line TB drugs, and more likely to have a history of being treated for TB two or more times.

Among this population, treatment failure was, not surprisingly, much more common when compared to other patients with MDR-TB. While relapse rate among "cured" patients also tended to be higher among patients with XDR-TB, the difference was not statistically significant.

"[Having] XDR-TB was the strongest predictor of both all-cause and TB-related mortality, and survival curves showed higher cumulative mortality among patients with XDR-TB than in other patients with MDR-TB," wrote Dr. Shim. Over the three to seven years that the study's patient population was monitored, approximately 50 percent of those identified with XDR-TB died, which was a mortality rate similar to untreated TB patients in South India, and one that becomes even worse with HIV co-infection.

Perhaps the biggest public health threat associated with XDR-TB, however, is not its particular virulence, but the lack of information and treatment options that medical and public health officials have on which to draw. The collective dearth of knowledge was likened by Giovanni Battista Migliori, M.D., Morgan Richardson, R.N., P.H.N., and Christopher Lange, M.D., Ph.D., co-authors of the accompanying editorial, to the proverbial blind men trying to describe an elephanttoo big a task to accomplish with too little information.

The risks of this lack of information are clear. "Regrettably, a new drug [to treat TB] has not been licensed in decades," they wrote, saying that only further research and concerted effort to understand and quantify the effects of the disease can really prevent MDR- and XDR-TB from becoming pandemic health crises.

"As we wait for new diagnostics and drugs that can meet the challenge of XDR-TB, we must work with what we presently have to create the optimal conditions for success and thus seize the opportunity we have to eliminate tuberculosis," they concluded.


Contact: Keely Savoie
American Thoracic Society

Related medicine news :

1. Breast Cancer Vaccine Works Against Deadlier Form of Disease
2. Gene Activity May Explain Deadlier Breast Cancers Among Younger Women
3. Deafness and seizures result when mysterious protein deleted in mice
4. Mysterious fevers of unknown origin: Could surgery be a cure?
5. Mysterious Disfiguring Disorder Responsible For Hair Loss in Over 11 Million American Women
Post Your Comments:
(Date:11/24/2015)... City, UT (PRWEB) , ... November 24, 2015 , ... ... Forbes Magazine. For a business, it is critical that the first impression be positive ... business, they are not likely to buy anything or want to return. They will ...
(Date:11/24/2015)... ... 2015 , ... In response to recent news highlighting Oxycodone fraud, Novus Medical ... the United States grew 400 percent between 1999 and 2010, far more than the ... percent of all fatal drug overdoses. (1) , While oxycodone and the extended release ...
(Date:11/24/2015)... ... November 24, 2015 , ... The American Association ... their local poison centers through donations on Tuesday, Dec. 1, 2015. Since 2012, ... day that inspires people to collaborate in improving their local communities and help ...
(Date:11/24/2015)... ... 24, 2015 , ... With Thanksgiving right around the corner, holiday travel season ... protect your family and vehicle. , According to the National Highway Traffic Safety Administration, ... is sharing the following safety tips from the NHTSA: , ...
(Date:11/24/2015)... ... November 24, 2015 , ... Abington Hospital ... Aetna Institute of Quality® Bariatric Surgery Facility for treating individuals living with morbid ... health care services available to its members to help them make informed decisions ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015   HeartWare International, Inc ... less-invasive, miniaturized circulatory support technologies that are revolutionizing the ... and Chief Executive Officer Doug Godshall is ... Annual Healthcare Conference on December 1, 2015 at ... 1-2 in New York . ...
(Date:11/24/2015)... 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ASDS ... of Directors has declared a special 1 percent stock dividend ... payable December 14, 2015, to shareholders of record December 7, ... additional shares of common stock. --> ... a strong endorsement of our confidence in Ascendant,s growth strategy ...
(Date:11/24/2015)... Nov. 24, 2015  Figure 1, a free mobile-first ... medical cases, has launched a new completely redesigned web ... version allows radiologists, who work primarily on a desktop, ... engage with its radiologist user base, Figure 1 is ... North America (RSNA) Annual Meeting. ...
Breaking Medicine Technology: